Trastuzumab Terminated Phase 2 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00088985Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
NCT01363986A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
NCT00674414Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery
NCT00824733Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00427427Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer
NCT00133796Neoadjuvant Herceptin in Patients With Breast Cancer
NCT01928615A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
NCT00453635Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
NCT00118053Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
NCT00138125Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT01690325Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
NCT01290718A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.